Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 3/20 | 0.34 |
| ▸ | CPT2 | P23786 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2966015 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CYP2D6TSHRCYP2C19HIF1A | |
| Water SCHEMBL2956340 | 0.97 | ALDH1A1 (0.40) | ALDH1A1CYP2D6TSHRCYP2C19HIF1A | |
| Water SCHEMBL29102063 | 0.97 | ALDH1A1 (0.40) | ALDH1A1CYP2D6TSHRCYP2C19HIF1A | |
| Water SCHEMBL2964492 | 0.97 | ALDH1A1 (0.40) | ALDH1A1CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL108616 | 0.97 | ALDH1A1 (0.43) | ALDH1A1CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL988732 | 0.95 | ALDH1A1 (0.42) | ALDH1A1CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL2315211 | 0.95 | ALDH1A1 (0.42) | ALDH1A1CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL4118128 | 0.95 | ALDH1A1 (0.42) | ALDH1A1CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL11021067 | 0.95 | ALDH1A1 (0.42) | ALDH1A1CYP2D6TSHRCYP2C19HIF1A | |
| SCHEMBL2487792 | 0.95 | ALDH1A1 (0.42) | ALDH1A1CYP2D6TSHRCYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053773-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | AUHUI TONGOO PHARMACEUTICAL TECH CO LTD (CN) | 2026-02-26 | — | — | US | claimed |
| US-20260042814-A1 | METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH & HUMAN SERVICES (US) | 2026-02-12 | — | — | US | claimed |
| EP-3784774-B1 | METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF | US HEALTH (US) | 2025-11-19 | — | — | EP | claimed |
| US-12415845-B2 | Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-09-16 | — | — | US | claimed |
| CN-118726256-A | Methods of producing T cell populations using hydroxycitric acid and/or salts thereof | 美国卫生和人力服务部 | 2024-10-01 | — | — | CN | claimed |
| CN-118320360-A | Easily-decomposed high-performance fire extinguishing coolant for aerosol fire extinguishing agent | 湖北及安盾消防科技有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-112262212-B | Methods of producing T cell populations using hydroxycitric acid and/or salts thereof | 美国卫生和人力服务部 | 2024-07-12 | — | — | CN | claimed |
| CN-116549427-A | New use of hydroxycitric acid for treating cholelithiasis and cholecystitis induced by cholelithiasis | 时珍本草生物科技(中山)有限公司 | 2023-08-08 | — | — | CN | claimed |
| CN-113831090-B | Large-flow-state anti-seepage impact-resistant grinding hydraulic concrete and preparation method thereof | 四川华西绿舍建材有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-113831090-A | Large-flow-state anti-permeability anti-impact grinding hydraulic concrete and preparation method thereof | 四川华西绿舍建材有限公司 | 2021-12-24 | — | — | CN | claimed |
| CN-110574894-A | nutritional meal replacement product capable of helping to eliminate vivotoxin and preparation method thereof | 江苏帝尔生物科技有限公司 | 2019-12-17 | — | — | CN | claimed |
| WO-2019035989-A1 | PREVENTION OF CALCIUM OXALATE KIDNEY STONES BY POTASSIUM HYDROXYCITRATE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-02-21 | — | — | WO | claimed |
| EP-1827139-A2 | SUPPLEMENT DIETARY COMPOSITION FOR PROMOTING WEIGHT LOSS | Lean Balance Formulations Ltd. (CA) | 2007-09-05 | — | — | EP | claimed |
| US-20070031526-A1 | Topical Deodorant Compositions Based on Hydroxycitric Acid | BIODERM RESEARCH (US) | 2007-02-08 | — | — | US | claimed |
| WO-2006133543-A1 | DIET SUPPLEMENTS FOR WEIGHT LOSS, DAYTIME ENERGY AND NIGHT TIME RELAXATION | EVERSLIM FORMULATIONS LTD. (CA) | 2006-12-21 | — | — | WO | claimed |
| US-20060286181-A1 | Diet supplements for causing fast weight loss, improving daytime energy, promoting nighttime relaxation and sleep, controlling appetite and/or increasing metabolism | 1695047 ONTARIO LTD. (CA) | 2006-12-21 | — | — | US | claimed |
| US-20060210650-A1 | Supplemental dietary composition for promoting weight loss | HALO FORMULATIONS LTD. (CA) | 2006-09-21 | — | — | US | claimed |
| WO-2006063443-A2 | SUPPLEMENT DIETARY COMPOSITION FOR PROMOTING WEIGHT LOSS | LEAN BALANCE FORMULATIONS LTD. (CA) | 2006-06-22 | — | — | WO | claimed |
| US-5783603-A | INCREASE FAT METABOLISM | SABINSA CORPORATION (US) | 1998-07-21 | — | — | US | claimed |
| WO-1996036585-A1 | A NEW PROCESS FOR THE PRODUCTION OF POTASSIUM HYDROXY CITRIC ACID, AND COMPOSITIONS CONTAINING THE POTASSIUM HYDROXY CITRIC ACID | SABINSA CORPORATION (US) | 1996-11-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053773-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | GLS, ATP6V1B1, PYGL | ALDH1A1 2726/4885CYP2D6 761/4885TSHR 4292/4885 |
| US-20260042814-A1 | METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF | NFATC1, SLC9A1, NHERF1 | ALDH1A1 2087/4885CYP2D6 2915/4885TSHR 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.